The ApoM/S1P-complex: its role in vascular inflammatory disease and interaction with S1P-receptors

Frej, Cecilia

2016

Document Version:
Publisher's PDF, also known as Version of record

Link to publication

Citation for published version (APA):
Frej, C. (2016). The ApoM/S1P-complex: its role in vascular inflammatory disease and interaction with S1P-receptors Lund: Lund University, Faculty of Medicine

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
HDL is believed to be protective against cardiovascular disease (CVD) via the reverse cholesterol transport and anti-inflammatory actions in the vessel. Apolipoprotein M (apoM) is an apolipoprotein mainly associated with HDL. Recently ApoM was proven to be the main carrier of Sphingosine 1-phosphate (S1P) in circulation. SIP is a signaling phospholipid involved in the immune system, exerting most of its effects through signaling via 5-G-protein coupled receptors; SIP1-5.

The aim of this thesis is to investigate the role of the apoM/SIP-complex in vascular inflammatory diseases such as atherosclerosis and sepsis. We also want to study the interaction between the apoM/SIP-complex and the SIP-receptors.

We developed a liquid chromatography-tandem mass spectrometry method for SIP-quantification in plasma and cell extracts. We found that plasma levels of SIP and apoM were decreased in sepsis, levels reflecting the severity of the disease. The apoM/SIP-complex contributes to the anti-inflammatory effects exerted by HDL as shown in vitro by its inhibiting potential of pro-inflammatory adhesion molecules on the endothelial surface and by its increment of the endothelial barrier function. Plasma levels of apoM and SIP in type-1-diabetes (T1D)-patients (who have increased risk of developing CVD) were not altered compared to healthy controls. However, HDL-particles from T1D showed decreased anti-inflammatory effects which was not related to reduced presence of apoM and S1P. The apoM/S1P-complex could interact with all SIP-receptors as shown by internalization of fluorescently labelled SIP-receptors overexpressed in HEK293-cells. Interestingly, extracellular levels of apoM and SIP could determine which receptor was available at the cellular surface.

In conclusion, our data suggest apoM and SIP to have a role in acute and chronic inflammation. Future research could help us clarify how the apoM/SIP-complex signals through the different SIP-receptors in different inflammatory disorders and hence contribute in developing new therapies against diseases in the vasculature.